Our Businesses

Regulated Markets

Your Trusted CMO/CDMO Partner in Global Healthcare
Driven by Quality, Powered by Partnerships

Fourrts is a well-respected, quality-focused contract manufacturing facility for customers in USA, United Kingdom, Europe, Australia, Canada, and other SRA countries.

Fourrts Plant II is a state-of-the-art US FDA/UK MHRA/EU GMP, Saudi FDA -approved facility with desktop approval from Canada and TGA Australia. We offer contract manufacturing services and formulation development.

Current production capacity is 4 billion tablets and 350 million capsules. The site is equipped with 6 granulation suites, 6 compression lines, 4 coating sections, and 9 packaging lines (7 blisters, 1 bottle and 1 Sachet). The site is also capable of manufacturing pellet-based products, as Granulation Suite 3 is equipped with both top and bottom spray FBE.

The state-of-the-art in-house Research and Development Lab—a miniature production facility—is supported by a dedicated team of scientists who are experienced in both product development and tech transfer.

Fourrts holds UK Market Authorization for Metformin F/c Tabs 500/850 mg; Ibuprofen F/c Tabs 200/400/600 mg; Paracetamol Tabs/Caps 500 mg; Propranolol Tabs 10/40 mg; Atenolol Tabs 25/50/100 mg; and Furosemide Tabs 20/40 mg.

Strategic Focus

  • Offering End-to-End CMO/CDMO Services for USA, Europe, UK, Canada, Middle East, LATAM, and Australia with world-class manufacturing and development expertise
  • Fourrts offers a dynamic pipeline at the forefront of value-added formulations and complex generics.
  • In-Licensing & Out-Licensing Opportunities – Expanding market reach through mutually beneficial collaborations.
  • Building a robust and diversified product portfolio to serve patients and partners worldwide.

For more information on plant – Click Here

Reach out for your business requirements:

Mr. K.S. VASU

Chief Executive – Finance & Business Development

Call

+91 98401 38611

(Ext- 303)

Mail